Does This Pharma Company's Lead Asset Make it a Buy Today?

Bipolar disorder is relatively common, with 2.8% of adults, or 6 million Americans, reporting symptoms over a 12-month period. Hence, the recent clinical success of Intra-Cellular Therapies' (NASDAQ: ITCI) antipsychotic drug, lumateperone, in the treatment of bipolar-related depression is a noteworthy catalyst for investors. Intra-Cellular Therapies secured its first-ever U.S. Food and Drug Administration (FDA) approval for Caplyta (lumateperone capsules) to treat schizophrenia in December 2019.